Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
GSK Signs For Two Late-Stage Compounds
February 12, 2007
| A version of this story appeared in
Volume 85, Issue 7
GlaxoSmithKline has agreed to codevelop XenoPort's XP13512, a prodrug of the pain treatment gabapentin that improves gabapentin's bioavailability. XP13512 is in Phase III trials for restless legs syndrome. XenoPort will get an up-front payment of $78 million and could reap milestone and other payments of up to $580 million. Separately, GSK will commercialize Fabre-Kramer Pharmaceuticals' gepirone ER, a 5HT1a agonist expected to be submitted to FDA this quarter as a treatment for major depressive disorder. Financial terms weren't disclosed.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X